

NCT ID	NCT05291156
Title	CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
Phase	Phase 2
Date Added	2022-03-22
Location	Italy
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Avelumab, cetuximab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05286814
Title	M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Phase	Phase 2
Date Added	2022-03-18
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT05277051
Title	First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Phase	Phase 1
Date Added	2022-03-14
Location	California, United States North Carolina, United States Oklahoma, United States Pennsylvania, United States Texas, United States Utah, United States Australia Canada China France Japan Korea, Republic of Spain United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Dostarlimab, GSK4381562
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05243862
Title	Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Phase	Phase 2
Date Added	2022-02-17
Location	Arizona, United States Florida, United States Minnesota, United States

Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, PolyPEPI1018, Tecentriq
Tags	MSS/ MMRp
NCT ID	NCT05239741
Title	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Phase	Phase 3
Date Added	2022-02-15
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd
NCT ID	NCT05217446
Title	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)
Phase	Phase 2
Date Added	2022-02-01
Location	Arizona, United States California, United States Florida, United States Illinois, United States Minnesota, United States New York, United States Tennessee, United States Texas, United States Australia Belgium Canada Czechia Denmark France Germany Italy Netherlands Norway Poland Slovakia Spain Sweden United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	encorafenib, Braftovi, Erbitux, Keytruda
Tags	MSI-H/ MMRd
NCT ID	NCT05215574
Title	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-01-31

Location	Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	NGM831, NGM831 plus pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05213195
Title	NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2022-01-28
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	NKG2D CAR-NK
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05205330
Title	A Phase Ib/Ila Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients
Phase	Phase 2
Date Added	2022-01-25
Location	Italy
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	AGEN2034, Balstilimab, CR6086
Tags	MSS/ MMRp
NCT ID	NCT05201612
Title	Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
Phase	Phase 2
Date Added	2022-01-21
Location	Spain
Prior IO Allowed	No
CRC-directed	Yes
Status	Unknown status
Drugs	Olaparib, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp